Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix
Annals of Oncology , Volume 18 - Issue 2 p. 275- 281
Objective: We carried out a phase II trial with BEMP [bleomycin, vindesine (Eldisine®), mitomycin C and cisplatin] in patients with recurrent and/or metastatic squamous cell carcinoma of the uterine cervix with the specific aim to assess whether BEMP was of particular interest when certain disease sites were involved. Patients and methods: Eligible patients received four cycles of E 3 mg/m2, day 1 + 8; P 50 mg/m2, day 1; B 15 mg/day (continuous infusion), day 2-4 and M 8 mg/m2, day 5 (on alternate cycles), every 3 weeks during an induction phase. Thereafter, those without progression continued with MEP every 4 weeks in a maintenance phase. MEP consisted of E 3 mg/m2, day 1 + 8, M 6 mg/m2(on alternate cycles) and P 50 mg/m2, both on day 1. All drugs were given i.v. Both response evaluation and toxicity grading were assessed according to World Health Organization criteria. Results: Of the 161 eligible patients, 143 were assessable for survival, 148 for toxicity and 131 for response. Overall response rate was 45% [complete (CR) 14.5%, partial response (PR) 30.5%]. Most responsive disease sites were lung, lymph nodes and skin metastases (>60% response, CR rate >25%). Median duration of response was 7.6 months. Survival was significantly better in patients with only distant metastases: 12.9 months versus 8.6 months in those with other disease sites involved (P = 0.002). In a multivariate analysis, patients with a good performance status yielded a better prognosis (P = 0.0017), as did the patients with only metastatic disease compared with those who had pelvic disease also or solely (P = 0.045). There were two toxic deaths and 21% of patients stopped treatment because of excessive toxicity. Conclusions: Patients with a good performance status and only distant metastases seem optimal candidates to receive the BEMP regimen. This benefit should be balanced against the expected serious toxic effects.
|, , , ,|
|Annals of Oncology|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
van Luijk, I.F, Coens, C, van der Burg, M.E.L, Kobierska, A, Namer, M, Lhomme, C, … Vermorken, J.B. (2007). Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix. Annals of Oncology, 18(2), 275–281. doi:10.1093/annonc/mdl384